February 07, 2026 09:36 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Big call from RBI: Repo rate stays at 5.25%, neutral stance continues | RG Kar scam twist: Court issues non-bailable warrant against whistle-blower Akhtar Ali | Court snub for Vijay: Madras HC rejects plea in ₹1.5 crore tax case | ‘We never said no’: Suryakumar Yadav says India ready for Pakistan clash at T20 World Cup | Supreme Court orders Mamata govt to clear pending dues | ‘India is free to buy oil from anyone’: Russia fires back at Trump’s crude deal claim | ‘Justice crying behind closed doors’: Mamata Banerjee slams ECI in Supreme Court, CJI Kant assures solution | Mummy, Papa, sorry: Three sisters jump to death after parents object to online gaming | Supreme Court raps Meta, WhatsApp: ‘Theft of private information, won’t allow its use’ | ‘Completely surrendered’: Congress slams Modi after Trump’s trade deal move
AstraZeneca

AstraZeneca CEO says firm found 'Winning Formula' for vaccine against COVID-19

| @indiablooms | Dec 28, 2020, at 04:12 pm

Moscow/Sputnik: AstraZeneca has found a "winning formula" to boost the efficacy of its vaccine against COVID-19, which has been developed in conjunction with the University of Oxford, CEO Pascal Soriot told the UK's Sunday Times newspaper.

The so-called Oxford vaccine had an average efficacy of 70 percent in clinical trials, although one dosing regimen, which saw participants given a half dose of the vaccine followed by a whole dose one month later, showed an efficacy rate of 90 per cent.

"We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else," Soriot told the newspaper.

The AstraZeneca CEO said that he was unable to provide full details of the optimum dosing regimen for the vaccine at this stage, adding that the results will be published at a later date.

Russia's Sputnik V vaccine against COVID-19, as well as vaccines produced by Pfizer/BioNTech and Moderna, have shown efficacy levels in excess of 90 percent during clinical trials.

The UK government has submitted purchase orders for 100 million doses of the Oxford vaccine against COVID-19. Plans are in the works for the vaccine to be rolled out to the public from January 4, the Sunday Telegraph newspaper reported earlier in the day.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.